The U.S. Food and Drug Administration has granted Humanitarian Use Device (HUD) status to Novocure‘s Tumor Treating Fields (TTFields) for treating pleural mesothelioma. The designation…

A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy.…

Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda…

Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will…

Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and…

Soluble mesothelin, a cell surface glycoprotein predominant in several types of cancer, is an independent prognostic marker and a new potential therapeutic target for patients…

Workers who are exposed to asbestos early in their career are at higher risk of developing pleural mesothelioma (PM) than those who were exposed later…

WASHINGTON, D.C. - Environmental Protection Agency (EPA) Administrator Scott Pruitt has promised to clean up decades-old Superfund sites, even as he is overseeing the rollback…